US Patent Number
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis.
University of Kentucky Research Foundation, Lexington, KY (US)
Ambati, Jayakrishna, "Toll like Receptor (TLR) Stimulation for Ocular Angiogenesis and Macular Degeneration" (2015). Ophthalmology and Visual Science Faculty Patents. 10.